

PTC Therapeutics, Inc. Investor Relations Department 100 Corporate Ct. South Plainfield, NJ 07080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: PTCT Last Trade: 18.34 Trade Time: 4:00 PM ET Jun 28, 2017 Change: 0.49 ♣ (+2.745%) Day Range 17.73 - 18.86 52-Week Range 4.03 - 18.69 Volume 659,142

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

... (more)

Stock Performance



Press Releases [View all]

Jun 22, 2017

New Analyses of Translarna™ (ataluren)

Data from ACT DMD Presented at the 12th

Annual European Pediatric Neurology Society

Congress

Jun 6, 2017

PTC Therapeutics Announces FDA Advisory
Committee Meeting for Ataluren for the
Treatment of Nonsense Mutation
Dystrophinopathy

Jun 5, 2017

PTC Therapeutics Announces Executive Promotions

Jun 2, 2017

PTC Therapeutics Reports Inducement
Grants Under Nasdag Listing Rule 5635(c)(4)

May 23, 2017

New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting

Financials [View all]

Mar 16, 2017 Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

May 8, 2017 Quarterly Report (10-Q)

Nov 3, 2016 Quarterly Report (10-Q)

Aug 4, 2016 Quarterly Report (10-Q)